Company profile
INNOCAN PHARMA Corp
OTC: INNPF · Healthcare · Drug Manufacturers - Specialty & Generic
Canadian filerHQ Calgary, ABReports USD
#517 of 1,418 Healthcare companies by revenue32nd-percentile growth
EA Score
59CFH 68DQ —GM 44SS 33
v0.1 · 45/100 weight · provisional
↑ 3-yr revenue growth, balance-sheet leverage · ↓ growth stability, listing tenure
Methodology →Revenue TTM
$25.2M
Rev growth YoY (TTM)
-17.3%
Net income (FY)
-$1.1M
Employees
11
as of 2026-08-23
Market cap
$7.2M
as of 2026-08-23
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$26.6M$26.6M2025
Net income-$1.1M-$1.1M2025
Operating income-$1.3M-$1.3M2025
Total assets$10.5M$10.5M2025
Liabilities$2.3M$2.3M2025
Equity$5.6M$5.6M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is INNOCAN PHARMA Corp’s revenue?
INNOCAN PHARMA Corp booked $26.6M in FY2025 revenue, contracting 9.6% year over year — slower than 68% of Healthcare companies we track, at a -4.2% net margin.
Peers · Healthcare
ImmuCell Corporation63CSensus Healthcare, Inc.51DCue Biopharma, Inc.50DCelularity Inc.31DNeurobiological Technologies, Inc.——Synovics Pharmaceuticals, Inc.——Key facts
CEOIris Bincovich
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersCalgary, AB
ExchangeOTC: INNPF
Employees11
IPO date2020-11-27
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.